Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 61.50
High: 61.50
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appt and Bank Funding

14 Feb 2007 07:01

Torex Retail PLC14 February 2007 Torex Retail plc (the "Company") Appointment of New Chairman and Increased Bank Funding Torex Retail plc, a leading global retail systems provider, today provides afurther update as to its board composition and financing arrangements. The Company announces that Steve Marshall has been appointed to the main Boardwith immediate effect as Non-executive Chairman. Mr Marshall has had aprestigious career in industry, including as CEO of both Railtrack PLC and ThornPLC, having also been group finance director at both companies. He is currentlynon-executive chairman of Delta PLC and a non-executive director of BalfourBeatty PLC and Southern Water Services Ltd. He was also executive chairman ofQueens Moat Houses PLC. This appointment follows those recently of Keith Taylor as Acting ChiefExecutive Officer and Iain Lynam as Chief Restructuring Officer, all of whichconsiderably strengthen the Board's operational and corporate restructuringexperience. The Company also announces that its syndicate of banks has agreed to provide therequested additional short-term working capital facility of £15.0 million. TheBoard considers that this will be sufficient to meet the Company's short-termworking capital requirements. The £15.0 million is in addition to the Company'sexisting total banking facilities of £152.5 million comprising term loans andoverdraft facilities. The Company expects to enter into further discussions with its bankers withrespect to its medium to long term financing requirements in the next fewmonths, when the Company has finalised results for the financial year ended 31December 2006 and has an up to date view of the 2007/2008 trading prospects. The Board is very pleased that it has concluded discussions with the Company'slenders with respect to its short-term financing requirements and that theCompany's lenders remain supportive. The Board is also delighted to haveappointed somebody of the calibre of Steve Marshall, whose experience andguidance will be of great benefit to the Company during this period. - Ends - Enquiries: Keith Taylor Acting CEO, Torex Retail plc Tel: 0870 300 6061 Ginny Pulbrook / Seb Hoyle / Lucie Holloway Citigate Dewe Rogerson Tel: 020 7638 9571 Additional details are set out below: Steve Marshall (age 50) Present directorships or partnerships: Delta PLC, Balfour Beatty PLC, SouthernWater Services Ltd Directorships or partnerships in previous five years: Queens Moat Houses PLC,Railtrack Group PLC Details of companies entering insolvency whilst a director or within 12 monthsof resignation: RT Group Holdings Ltd No unspent convictions, bankruptcy or IVAs, no receivership of assets, no publiccriticism by regulatory bodies. There is nothing further to disclose in relation to their appointment pursuantto Rule 17 of the AIM Rules. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.